Publications<< Back

Diaz-Ricart M, Escolar G

Vorapaxar for the reduction of atherothrombotic events.

Drugs Today. 2014 Nov;50(11):747-56, PMID: 25525635

Vorapaxar is a novel platelet inhibitor that potently and selectively inhibits thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen via antagonism of the platelet proteinase-activated receptor PAR1. Vorapaxar is a non-peptide himbacine analogue that has been developed for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.

PHARMACOLOGY & PHARMACY